Outcome

Itron and SmartThings Join Forces to Unlock Utility Energy Analytics for Carbon Reduction

Retrieved on: 
Monday, September 26, 2022
IOT (Internet of Things), Alternative Energy, Data Management, Energy, Green Technology, Technology, Apps, Applications, Other Natural Resources, Environment, Natural Resources, Other Technology, Software, Networks, Other Energy, Utilities, Software, ITRI, Carbon, IOS, Time, Samsung Electronics, Safety, City, DI, Outcome, Industry, Television, Industrial internet of things, Electricity, Technology, Quality of life, Samsung, Zigbee, Goal, Solution, CA, Ecosystem, NASDAQ, EV, Android, SmartThings, Water, EVP, Connectivity, Water resources, IOT, Renewable energy, Consumer electronics, Mobile phone, Itron

The collaboration will combine Itrons proven distributed intelligence (DI) ecosystem, which features millions of connected endpoints, with SmartThings Energy service1 to provide real-time energy readings and consumption patterns to improve energy management and conservation.

Key Points: 
  • The collaboration will combine Itrons proven distributed intelligence (DI) ecosystem, which features millions of connected endpoints, with SmartThings Energy service1 to provide real-time energy readings and consumption patterns to improve energy management and conservation.
  • Enhancing value to utility Utilities will be able to engage the rapidly growing base of SmartThings app users to enroll in energy efficiency, demand response and EV charging programs.
  • Enhancing the enrollment experience SmartThings enhanced enrollment experience can be applied into utility programs for energy efficiency, demand response, and EV charging directly from the SmartThings application.
  • We are thrilled to collaborate with Itron as this not only conserves energy but also aligns with our customers goals of achieving net-zero carbon households.

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates

Retrieved on: 
Monday, September 26, 2022
Center, Virus, World, Bed, Pressure, Outcome, Patient, Immunodeficiency, Oral, CDC, Disease, Season, CSL Limited, MPH, CSL, ASX, Profile, COVID-19, Selection bias, Organization, Antibody, Urinary tract infection, Veneto, Ageing, Hospital, Haemophilia, CSL Behring, Population, Degenerative disease, Ministry of Women and Vulnerable Populations, Vaccine, Korea Disease Control and Prevention Agency, WHO, Incidence, Control, World Health Organization, Vaccination, ER, Risk, Death, Biotechnology, R, Health insurance, EU, Influenza, MD, Epidemiology, ICU

The data are being presented in oral and poster sessions at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.

Key Points: 
  • The data are being presented in oral and poster sessions at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.
  • This will become even more important in a world where COVID-19 and influenza are likely to continue co-circulating."
  • "8
    As a global leader in influenza protection, CSL Seqirus recognizes its responsibility to help reduce the burden of influenza on health systems and communities, including vulnerable populations like children, around the world.
  • In the region of Italy for which hospitalization data was available, 12,416 influenza cases were reported from January 2017 to March 2020.

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Retrieved on: 
Monday, September 12, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Hospital, Risk, Therapy, Safety, Haematopoietic system, Infection, COVID-19, Transplant, Twitter, Lymphatic system, Global, FDA, HSCT, Hematology, 2009 Davis Cup, Phenotype, LinkedIn, Functional Assessment of Cancer Therapy - General (FACT-G), Quality of life, Breakthrough therapy, Private Securities Litigation Reform Act, Outcome, PDUFA, U.S. Securities and Exchange Commission, NK, Patient, Facebook, Immunotherapy, Technology, Instagram, Cell, Bone marrow, B cell, RTE, UCB, Security (finance), Graft-versus-host disease, BLA, Diversity, SEC, Mortality, NAM, Trial of the century, Pharmaceutical industry, Medicine, Dentistry, EU, Black

The data suggest meaningfully greater preservation or improvement of important HRQL domains in patients treated with omidubicel compared to UCB.

Key Points: 
  • The data suggest meaningfully greater preservation or improvement of important HRQL domains in patients treated with omidubicel compared to UCB.
  • Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

Decision Intelligence Highlighted at Israel Hi-Tech Conference 2022

Retrieved on: 
Thursday, September 8, 2022
Other Professional Services, Software, Data Analytics, Consulting, Artificial Intelligence, Data Management, Professional Services, Technology, Machine learning, DI, Outcome, Decision intelligence, AI, Human, Technology, CEO, Dell, JVP, Work, Artificial intelligence, Solution, Bridge Growth Partners, NVIDIA, Cognition, Entrepreneurship, Decision, Computer, Â, Pyramid Analytics, BDA, Business intelligence, High tech, Microsoft Power BI, Multimedia, Organization, Sequoia Capital, Thought, Conference, CAGR, Intelligence, Jerusalem Venture Partners, IDC, Tableau, Data science, Climate change, Growth, Health, Geography, Pyramid, Business analytics, Medical device, Management, Renewable energy, Lithium, Cryptocurrency, Google

Israel Hi-Tech Conference 2022 recently put Decision Intelligence center stage, with main stage presentations from Omri Kohl, the CEO and co-founder of Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, and Dr. Lorien Pratt , Chief Scientist at Quantellia and the co-inventor of Decision Intelligence.

Key Points: 
  • Israel Hi-Tech Conference 2022 recently put Decision Intelligence center stage, with main stage presentations from Omri Kohl, the CEO and co-founder of Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, and Dr. Lorien Pratt , Chief Scientist at Quantellia and the co-inventor of Decision Intelligence.
  • (Photo: Business Wire)
    Dr. Pratt outlined why Decision Intelligence is the link to connect decision makers with data and analytics, addressing the persistent underutilization of data-driven insights by businesses today.
  • According to Gartner research , Decision Intelligence will be used by one-third of all large organizations by next year.
  • Today she is one of the leading visionaries on Decision Intelligence, having recently published a book on the topic: How Decision Intelligence Connects Data, Actions and Outcomes for a Better World.

Cardinal Health Announces Pharmaceutical Segment Organizational Changes

Retrieved on: 
Thursday, September 8, 2022
National Association, Outcome, CEO, NYSE, View, Dartmouth College, Wholesaling, Time, Culture, Pharmacy, Board, Pharmaceutical distribution, Northwestern University, Hollar, Multimedia, J. P. Morgan, Cardinal Health, Leadership, History, Company, Medication, Knowledge, Director, Ecosystem, CAH, Environment, Pharmaceutical industry, Management, Healthcare

DUBLIN, Ohio, Sept. 8, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced Debbie Weitzman, current President of Pharmaceutical Distribution, will become CEO of the Company's Pharmaceutical Segment. Weitzman will replace Victor Crawford, who will be stepping down as Pharmaceutical Segment CEO effective September 19, but will remain with the company until November 13 to help with the transition. The role of President of Pharmaceutical Distribution will be eliminated.

Key Points: 
  • DUBLIN, Ohio, Sept. 8, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced Debbie Weitzman, current President of Pharmaceutical Distribution, will become CEO of the Company's Pharmaceutical Segment.
  • The company has further streamlined the Pharmaceutical Segment by restructuring and eliminating additional roles.
  • As a result of these changes, the Pharmaceutical and Specialty Distribution businesses will both report directly to Debbie Weitzman.
  • "Debbie has been a tremendous leader at Cardinal Health, and we believe her knowledge and experience make her the right person to lead our redesigned Pharmaceutical Segment," said Jason Hollar, Chief Executive Officer of Cardinal Health.

CommonSpirit Health at Home and ExactCare improve Patient Outcomes with Integrated Access to Comprehensive Pharmacy Services at Home

Retrieved on: 
Thursday, September 1, 2022
Dignity, Medication, Doctor of Pharmacy, Patient, Conditional sentence, Dignity Health, OASIS, Oral, Time, Solution, Catholic Health Initiatives, MTM, CommonSpirit Health, Outcome, Home, Physician, PT, Health, Reconciliation (United States Congress), MHA, Hospital, Medication therapy management, GLOBE, Medicare, Pharmacy, Population, DPT, Medicine, Pharmaceutical industry

A recent analysis demonstrated better outcomes for an important home health quality measureOASIS M2020: Improvement in Management of Oral Medicationsfor CommonSpirit Health at Home patients receiving comprehensive long-term pharmacy services from ExactCare.

Key Points: 
  • A recent analysis demonstrated better outcomes for an important home health quality measureOASIS M2020: Improvement in Management of Oral Medicationsfor CommonSpirit Health at Home patients receiving comprehensive long-term pharmacy services from ExactCare.
  • This demonstrates that providing patients access to comprehensive pharmacy services enhances the successful transition of medication therapies into the home environment.
  • ExactCare and CommonSpirit Health at Home have partnered for more than two years to provide comprehensive long-term pharmacy care to people at home.
  • CommonSpirit Health at Home is proud to be part of CommonSpirit Health, the largest non-profit health care system in the country.

Innovator ETFs Announces New Upside Caps for September Series of U.S. Equity Buffer ETFs™

Retrieved on: 
Thursday, September 1, 2022
COVID-19, Prospectus, Risk, Government, Emerging market, Sale, Option, Outcome, Fund, Consultant, Funding, OCC, ETF, AUM, Investment, Lovell Minnick Partners, FLEX, LLC, Options Clearing Corporation, Structuring, Milliman, Security (finance), Life insurance, Bank, Risk management, Financial adviser

CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Innovator Capital Management, LLC (Innovator) today announced the new upside caps and return profiles for the September series of the U.S. Equity Buffer ETFs™ – Innovator U.S. Equity Buffer ETF™ – September (BSEP), Innovator U.S. Equity Power Buffer ETF™ – September (PSEP) and Innovator U.S. Equity Ultra Buffer ETF™ – September (USEP) – which completed their third annual outcome period and reset at the end of the month. The 36 total ETFs in the flagship U.S. Equity Buffer ETF lineup seek to provide investors with upside participation, to a cap, in Large-cap U.S. stocks via options on the SPDR S&P 500 ETF Trust (SPY) with buffers against market losses of 9%, 15% or 30% over one-year periods. With the stock market drawdown in 2022, the September series of Innovator’s U.S. Equity Buffer ETFs shielded investors who held shares since the beginning of the just completed outcome period from a portion of SPY losses through August.

Key Points: 
  • Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.
  • The outbreak of COVID-19 has negatively affected the worldwide economy, individual countries, individual companies and the market in general.
  • Consequently, ETFs usually generate fewer capital gain distributions overall, which can make them somewhat more tax-efficient than mutual funds.
  • 5 Defined Outcome ETFs are not backed by the faith and credit of an Issuing institution, so they are not exposed to credit risk.

Innovator ETFs Announces Latest Upside Cap Ranges for September Series of U.S. Equity Buffer ETFs™

Retrieved on: 
Thursday, August 25, 2022
COVID-19, Prospectus, Risk, Government, Emerging market, Sale, Option, Outcome, Fund, Consultant, Funding, OCC, ETF, AUM, Investment, Lovell Minnick Partners, FLEX, LLC, Options Clearing Corporation, Structuring, Milliman, Security (finance), Life insurance, Bank, Risk management, Financial adviser

The outbreak of COVID-19 has negatively affected the worldwide economy, individual countries, individual companies and the market in general.

Key Points: 
  • The outbreak of COVID-19 has negatively affected the worldwide economy, individual countries, individual companies and the market in general.
  • The future impact of COVID-19 is currently unknown, and it may exacerbate other risks that apply to the Fund.
  • 2 ETFs use creation units, which allow for the purchase and sale of assets in the fund collectively.
  • Consequently, ETFs usually generate fewer capital gain distributions overall, which can make them somewhat more tax-efficient than mutual funds.

Alorica Named as a Leader in Everest Group’s Customer Experience Management (CXM) in the Americas 2022

Retrieved on: 
Tuesday, August 16, 2022
Technology, Marketing, Other Technology, Communications, Professional Services, Business, Software, Digital Marketing, Data Analytics, Data Management, Matrix, Outcome, Theretra alorica, Industry, CX, Customer service, Investment, Inc., CXM, PEAK, Â, Solution, OAA, Risk management, Technology

Alorica Inc. , a trusted global provider of next-generation customer experience (CX) solutions, has been acknowledged as a Leader in Everest Groups Customer Experience Management (CXM) in the Americas Service Provider Landscape with PEAK Matrix Assessment 2022.

Key Points: 
  • Alorica Inc. , a trusted global provider of next-generation customer experience (CX) solutions, has been acknowledged as a Leader in Everest Groups Customer Experience Management (CXM) in the Americas Service Provider Landscape with PEAK Matrix Assessment 2022.
  • Major organizations worldwide trust the groups unbiased evaluation of factors, including vision, capabilities/functionality, talent availability, market success/impact, and cost.
  • Aloricas Leader position in the PEAK Matrix Assessment highlights the companys strategic approach in delivering for its diverse clientele and supporting its 100,000 employees.
  • The PEAK Matrix Assessment for the Americas placement takes its place alongside several other notable accolades for Alorica in 2022 to date.

DISQO LAUNCHES OUTCOMES LIFT FOR CROSS-PLATFORM AD MEASUREMENT

Retrieved on: 
Wednesday, August 3, 2022
APCO, Deloitte Technology Fast 500, APCO Worldwide, Marketing, Mediacom, Adidas, Intelligence, VP, ROI, GoodRx, KPI-driven code analysis, EVP, Multimedia, Advertising, CX, Industry, LinkedIn, Technology, Outcome, Touchpoint, Ecosystem, OLV, Twitter, Friction, IDS, View, CTV, Online shopping, Public relations, Vevo, Deloitte, Analytics

LOS ANGELES, Aug. 3, 2022 /PRNewswire/ -- Leading customer experience (CX) intelligence platform DISQO today announced the launch of Outcomes Lift, the industry's first product measuring the full incremental impact of cross-platform advertising campaigns on marketing funnel outcomes. Outcomes Lift provides advertisers with increased visibility into the entire customer experience journey, everything from search to e-commerce transactions, formerly obscured by limited access and deprecated methodologies.

Key Points: 
  • DISQO today announced the launch of Outcomes Lift measuring the impact of cross-platform ad campaigns on outcomes.
  • DISQO Outcomes Lift is seeing hyper growth with brands, agencies and publishers, including blue-chip clients like Adidas, APCO, CROSSMEDIA.
  • "DISQO's Outcomes Lift has helped us show the specific behavioral impacts that happen post ad exposure on Vevo, expanding our measurement toolkit."
  • Outcomes Lift empowers advertisers to future-proof their measurement against new platform silos and ad formats, as well as identifier technology disruptions down the line.